(a) There is hereby established a council to be called the "Advisory Council on Alzheimer's Disease Research and Treatment." The advisory council shall consist of thirteen (13) members to be composed as follows: the lieutenant governor, or designee; the director of the department of health, or designee; the director of the office of healthy aging, or designee; the chairperson of the long-term care coordinating council; one member appointed by the speaker of the house; one member appointed by the president of the senate; and seven (7) members appointed by the governor. The members appointed by the governor shall include one member who is an Alzheimer's disease patient advocate; one member who is an Alzheimer's disease caregiver; one member who is a healthcare provider; one member who is a researcher with Alzheimer's-related expertise in basic, translational, clinical, or drug-development science; one member who is a representative from an Alzheimer's disease organization that funds research and has demonstrated experience in care and patient services; one member from an Alzheimer's advocacy organization that provides services to families and professionals, including information and referrals, support groups, care consultation, education, and safety services; and one member who is a representative of a healthcare insurer. Advisory council members shall select their own chairperson. Seven (7) members shall constitute a quorum.
(b) The member appointed by the speaker of the house,, the member appointed by the president of the senate, and three (3) members appointed by the governor shall be initially appointed for a term to expire July 1, 2020, and four (4) members to be appointed by the governor shall be initially appointed for a term to expire July 1, 2021. After the initial term, the appointed members shall serve two-year (2) terms, until their successor is appointed.
History of Section.
P.L. 2019, ch. 174, § 1; P.L. 2019, ch. 209, § 1.